Merck & Co., Inc. $MRK Shares Bought by Strategy Asset Managers LLC

Strategy Asset Managers LLC raised its position in Merck & Co., Inc. (NYSE:MRK) by 31.9% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 48,703 shares of the company’s stock after purchasing an additional 11,779 shares during the quarter. Merck & Co., Inc. accounts for approximately 0.9% of Strategy Asset Managers LLC’s holdings, making the stock its 29th biggest holding. Strategy Asset Managers LLC’s holdings in Merck & Co., Inc. were worth $7,077,000 at the end of the most recent quarter.

Other institutional investors have also added to or reduced their stakes in the company. Round Rock Advisors LLC grew its stake in shares of Merck & Co., Inc. by 0.7% during the second quarter. Round Rock Advisors LLC now owns 9,901 shares of the company’s stock valued at $1,272,000 after buying an additional 66 shares during the last quarter. Cascade Financial Partners LLC raised its holdings in shares of Merck & Co., Inc. by 0.5% in the second quarter. Cascade Financial Partners LLC now owns 14,746 shares of the company’s stock worth $1,895,000 after buying an additional 80 shares during the period. Somerset Trust Co raised its holdings in shares of Merck & Co., Inc. by 0.9% in the second quarter. Somerset Trust Co now owns 8,701 shares of the company’s stock worth $1,118,000 after buying an additional 81 shares during the period. Stonebridge Financial Group LLC lifted its stake in shares of Merck & Co., Inc. by 0.9% during the 2nd quarter. Stonebridge Financial Group LLC now owns 8,747 shares of the company’s stock worth $1,124,000 after acquiring an additional 81 shares during the last quarter. Finally, Stronghold Wealth Management L.L.C. lifted its stake in shares of Merck & Co., Inc. by 2.6% during the 2nd quarter. Stronghold Wealth Management L.L.C. now owns 3,237 shares of the company’s stock worth $416,000 after acquiring an additional 82 shares during the last quarter. Institutional investors own 76.07% of the company’s stock.

Insider Activity at Merck & Co., Inc.

In other Merck & Co., Inc. news, EVP Richard R. Deluca sold 20,784 shares of the company’s stock in a transaction on Monday, August 10th. The stock was sold at an average price of $130.43, for a total value of $2,710,857.12. Following the completion of the sale, the executive vice president directly owned 134,703 shares in the company, valued at approximately $17,569,312.29. This represents a 13.37% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP David R. Maraldo sold 18,706 shares of the company’s stock in a transaction on Wednesday, August 5th. The stock was sold at an average price of $128.72, for a total value of $2,407,836.32. Following the completion of the sale, the executive vice president owned 18,212 shares of the company’s stock, valued at $2,344,248.64. This represents a 50.67% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 228,238 shares of company stock worth $29,977,783 over the last three months. Corporate insiders own 0.17% of the company’s stock.

More Merck & Co., Inc. News

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Keytruda and pipeline catalysts support Q3 optimism. Continued Keytruda sales growth, expanded indications and newer launches could help Merck exceed third-quarter expectations. Will Keytruda Continue to Aid Merck’s Top Line in Q3 Earnings?
• Positive Sentiment: Oncology pipeline data is an important longer-term catalyst. Merck plans to present first-time pivotal Phase 3 results from three studies and more than 90 additional abstracts at ESMO 2026, potentially providing evidence of growth opportunities as Keytruda eventually faces biosimilar pressure. Merck ESMO 2026 Oncology Pipeline Announcement
• Positive Sentiment: Management sounded constructive on the Moderna cancer vaccine partnership. CEO Rob Davis said manufacturing of the personalized cancer vaccine should become faster and more efficient as Merck and Moderna refine the complex production process. Merck CEO Discusses Cancer Vaccine Manufacturing
• Positive Sentiment: Leerink Partners initiated or reiterated a Buy rating on Merck, adding favorable analyst sentiment. Merck Gets a Buy Rating from Leerink Partners

Wall Street Analysts Forecast Growth

A number of equities analysts recently issued reports on MRK shares. Wolfe Research boosted their price objective on Merck & Co., Inc. from $155.00 to $180.00 and gave the company an “outperform” rating in a report on Tuesday, August 25th. Citigroup increased their target price on Merck & Co., Inc. from $125.00 to $145.00 and gave the stock a “neutral” rating in a research note on Monday. Barclays increased their target price on Merck & Co., Inc. from $140.00 to $150.00 and gave the stock an “overweight” rating in a research note on Wednesday, July 29th. CICC Research initiated coverage on Merck & Co., Inc. in a research report on Wednesday, June 24th. They set an “outperform” rating and a $138.00 target price for the company. Finally, The Goldman Sachs Group boosted their target price on shares of Merck & Co., Inc. from $140.00 to $160.00 and gave the company a “buy” rating in a research note on Friday, August 21st. Seventeen research analysts have rated the stock with a Buy rating and ten have issued a Hold rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $151.92.

Merck & Co., Inc. Price Performance

Shares of MRK stock opened at $147.47 on Thursday. The company has a debt-to-equity ratio of 1.22, a current ratio of 1.32 and a quick ratio of 1.10. The company has a market capitalization of $363.83 billion, a P/E ratio of 117.97, a P/E/G ratio of 6.56 and a beta of 0.21. The company’s 50-day simple moving average is $144.91 and its two-hundred day simple moving average is $128.93. Merck & Co., Inc. has a one year low of $82.01 and a one year high of $156.92.

Merck & Co., Inc. (NYSE:MRK) last issued its earnings results on Tuesday, August 4th. The company reported ($0.13) EPS for the quarter, topping analysts’ consensus estimates of ($0.26) by $0.13. Merck & Co., Inc. had a net margin of 4.77% and a return on equity of 16.73%. The business had revenue of $16.61 billion for the quarter, compared to analyst estimates of $16.37 billion. During the same period last year, the company posted $2.13 earnings per share. The company’s quarterly revenue was up 5.1% compared to the same quarter last year. Merck & Co., Inc. has set its FY 2026 guidance at 2.660-2.760 EPS. As a group, equities analysts anticipate that Merck & Co., Inc. will post 2.66 EPS for the current year.

Merck & Co., Inc. Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Wednesday, October 7th. Investors of record on Tuesday, September 15th were paid a $0.85 dividend. The ex-dividend date of this dividend was Tuesday, September 15th. This represents a $3.40 annualized dividend and a yield of 2.3%. Merck & Co., Inc.’s dividend payout ratio is 272.00%.

Merck & Co., Inc. Company Profile

Merck & Co, Inc is a global healthcare company that develops and markets prescription medicines, vaccines, and animal-health products. The company serves patients, healthcare providers, and customers in markets around the world, with research and commercial operations spanning multiple geographic regions.

Its pharmaceutical portfolio includes oncology, infectious-disease, cardiovascular, immunology, and other therapeutic areas. Key products include Keytruda, an oncology treatment; Gardasil, a human papillomavirus (HPV) vaccine; Januvia and Janumet for type 2 diabetes; Bridion for anesthesia-related use; and Winrevair for pulmonary arterial hypertension.